Karius Inc, Redwood City, Calif, has raised $50 million in Series A equity financing. Funds will be used to support ongoing and new clinical trials, scale up laboratory capacity, and advance commercialization of the Karius test, which uses a combination of machine learning, proprietary genomics algorithms, and next-generation sequencing to enable the broad and rapid detection of more than 1,250 pathogens.

Existing investors Data Collective (DCVC) and Lightspeed Venture Partners co-led the financing, with major participation from new investors including Tencent and Khosla Ventures. Existing investors Innovation Endeavors and Spectrum 28 participated as well.

The company recently moved into a new 25,000-square foot facility, significantly increasing laboratory space and capacity to process more tests.

Using a standard blood draw, the Karius test identifies cell-free DNA fragments left by bacteria, viruses, fungi, and other eukaryotic pathogens in a patient’s bloodstream, even when living organisms are no longer detectable in the blood.

“We’re excited to partner with this world-class group of investors and innovators to help us conquer infectious diseases using the power of genomics,” says Mickey Kertesz, PhD, CEO at Karius. “Infectious diseases are a leading cause of mortality globally and an enormous area of unmet need. Clinical results from our early access program demonstrate that the Karius test allows clinicians to diagnose infections more rapidly and accurately.

“We’ve enabled doctors to devise precise and effective treatment plans for patients and speed recovery times,” Kertesx adds. “We look forward to further broadening availability of our technology in the coming months.”

“We seeded and have doubled-down on financing Karius for two reasons,” says Matt Ocko, managing partner at DCVC. “First, because the core team has already significantly advanced sequencing with their previous company, which we also helped finance and that was ultimately acquired by Illumina. Secondly, and more importantly, Karius is providing doctors with critical information that can save lives that would be otherwise lost to infectious disease. This new financing will help Karius do this on a global scale.”

“I am passionate about the potential of Karius’ technology to save lives, and I couldn’t be more excited to see what the team has accomplished since the core technology spun out of my lab,” says Stephen Quake, PhD, Karius Scientific cofounder and copresident of the Chan Zuckerberg Biohub.

The Karius Digital Culture test applies advanced sequencing and analytics for the broad and rapid detection of microbial cell-free DNA through a standard blood draw. Unlike conventional culture and panel testing methods that test for a narrow range of pathogens, the Karius test can detect more than 1,250 pathogens, typically within 1 business day.

For more information, visit Karius.